Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2025 | -$0.22 | -$0.26 | Miss |
| May 8, 2025 | -$0.26 | -$0.35 | Miss |
| Mar 27, 2025 | -$0.36 | -$0.29 | Beat |
| Nov 7, 2024 | -$0.31 | -$0.33 | Miss |
| Aug 8, 2024 | -$0.29 | -$0.26 | Beat |
| May 15, 2024 | -$0.33 | -$0.20 | Beat |